Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023

Standard

Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023. / Diel, Roland; Breuer, Cornelia; Bös, Lena; Geerdes-Fenge, Hilte; Günther, Annette; Häcker, Brit; Hannemann, Jörg; Nienhaus, Albert; Priwitzer, Martin; Witte, Peter; Bauer, Torsten.

In: PNEUMOLOGIE, Vol. 77, No. 9, 09.2023, p. 607-631.

Research output: SCORING: Contribution to journalGuideline, recommendation, statementResearchpeer-review

Harvard

Diel, R, Breuer, C, Bös, L, Geerdes-Fenge, H, Günther, A, Häcker, B, Hannemann, J, Nienhaus, A, Priwitzer, M, Witte, P & Bauer, T 2023, 'Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023', PNEUMOLOGIE, vol. 77, no. 9, pp. 607-631. https://doi.org/10.1055/a-2107-2147

APA

Diel, R., Breuer, C., Bös, L., Geerdes-Fenge, H., Günther, A., Häcker, B., Hannemann, J., Nienhaus, A., Priwitzer, M., Witte, P., & Bauer, T. (2023). Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023. PNEUMOLOGIE, 77(9), 607-631. https://doi.org/10.1055/a-2107-2147

Vancouver

Diel R, Breuer C, Bös L, Geerdes-Fenge H, Günther A, Häcker B et al. Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023. PNEUMOLOGIE. 2023 Sep;77(9):607-631. https://doi.org/10.1055/a-2107-2147

Bibtex

@article{828a283bd7c1429d8dd3fa8f229376c2,
title = "Empfehlungen f{\"u}r die Umgebungsuntersuchungen bei Tuberkulose – Update 2023",
abstract = "The aim of contact tracing for tuberculosis is in addition to active case finding the detection of chains of infection and the prevention of the further spread of the disease. In this context, a careful selection of contact persons is necessary, depending on the type and duration of contact, to identify persons who are recently infected and therefore to increase the benefit of a preventive therapy and to avoid unnecessary testing of persons who are not at risk of infection. Since the last update of the recommendations on contact tracing, data on the use of interferon-y release assays (IGRAs) in children has been improved markedly. These are the preferred test in contact tracing of adults. For children, both IGRAs and the tuberculin skin test can be used equivalently. Rifampicin for 4 months, rifampicin and isoniazid for 3 months, or isoniazid for 9 months are recommended as preventive therapy in cases of confirmed infection.The implementation of the contact tracing in different age groups as well as legal framework conditions and socio-medical aspects and challenges are dealt with in detail. In addition, special cases, such as environmental screening in day-care centers, schools, or other community facilities, are discussed separately.",
author = "Roland Diel and Cornelia Breuer and Lena B{\"o}s and Hilte Geerdes-Fenge and Annette G{\"u}nther and Brit H{\"a}cker and J{\"o}rg Hannemann and Albert Nienhaus and Martin Priwitzer and Peter Witte and Torsten Bauer",
note = "Thieme. All rights reserved.",
year = "2023",
month = sep,
doi = "10.1055/a-2107-2147",
language = "Deutsch",
volume = "77",
pages = "607--631",
journal = "PNEUMOLOGIE",
issn = "0934-8387",
publisher = "Georg Thieme Verlag KG",
number = "9",

}

RIS

TY - JOUR

T1 - Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose – Update 2023

AU - Diel, Roland

AU - Breuer, Cornelia

AU - Bös, Lena

AU - Geerdes-Fenge, Hilte

AU - Günther, Annette

AU - Häcker, Brit

AU - Hannemann, Jörg

AU - Nienhaus, Albert

AU - Priwitzer, Martin

AU - Witte, Peter

AU - Bauer, Torsten

N1 - Thieme. All rights reserved.

PY - 2023/9

Y1 - 2023/9

N2 - The aim of contact tracing for tuberculosis is in addition to active case finding the detection of chains of infection and the prevention of the further spread of the disease. In this context, a careful selection of contact persons is necessary, depending on the type and duration of contact, to identify persons who are recently infected and therefore to increase the benefit of a preventive therapy and to avoid unnecessary testing of persons who are not at risk of infection. Since the last update of the recommendations on contact tracing, data on the use of interferon-y release assays (IGRAs) in children has been improved markedly. These are the preferred test in contact tracing of adults. For children, both IGRAs and the tuberculin skin test can be used equivalently. Rifampicin for 4 months, rifampicin and isoniazid for 3 months, or isoniazid for 9 months are recommended as preventive therapy in cases of confirmed infection.The implementation of the contact tracing in different age groups as well as legal framework conditions and socio-medical aspects and challenges are dealt with in detail. In addition, special cases, such as environmental screening in day-care centers, schools, or other community facilities, are discussed separately.

AB - The aim of contact tracing for tuberculosis is in addition to active case finding the detection of chains of infection and the prevention of the further spread of the disease. In this context, a careful selection of contact persons is necessary, depending on the type and duration of contact, to identify persons who are recently infected and therefore to increase the benefit of a preventive therapy and to avoid unnecessary testing of persons who are not at risk of infection. Since the last update of the recommendations on contact tracing, data on the use of interferon-y release assays (IGRAs) in children has been improved markedly. These are the preferred test in contact tracing of adults. For children, both IGRAs and the tuberculin skin test can be used equivalently. Rifampicin for 4 months, rifampicin and isoniazid for 3 months, or isoniazid for 9 months are recommended as preventive therapy in cases of confirmed infection.The implementation of the contact tracing in different age groups as well as legal framework conditions and socio-medical aspects and challenges are dealt with in detail. In addition, special cases, such as environmental screening in day-care centers, schools, or other community facilities, are discussed separately.

U2 - 10.1055/a-2107-2147

DO - 10.1055/a-2107-2147

M3 - Leitlinie, Empfehlung, Stellungnahme

C2 - 37536363

VL - 77

SP - 607

EP - 631

JO - PNEUMOLOGIE

JF - PNEUMOLOGIE

SN - 0934-8387

IS - 9

ER -